Connect with us

Healthcare Buzz

Glenmark and Helsinn Partner to Launch Akynzeo in India and Nepal

Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, and Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, have entered into an exclusive licensing agreement to introduce Akynzeo in India and Nepal. Akynzeo, an oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV). The licensing agreement with Glenmark for Akynzeo represents Helsinn’s first such agreement in India. Glenmark will have exclusive marketing rights for Akynzeo in India and Nepal. Glenmark has received marketing approval for Akynzeo from the Central Drugs Standard Control Organization (CDSCO).

Akynzeo is the first and only combination anti-emetic prophylaxis with high complete response rates for 5 days in cancer chemotherapy treated patients, having demonstrated 90 percent complete response rates through 5 days compared to 77 percent for oral palonosetron in patients receiving HEC cisplatin-based chemotherapy. It has been included among the recommended options in the MASCC/ESMO, ASCO, and NCCN antiemesis guidelines. Delayed nausea is still a problem for up to 82 percent of patients receiving MEC (moderately emetogenic chemotherapy) and HEC (highly emetogenic chemotherapy), representing a significant unmet medical need.

“I am sure the launch of Akynzeo will fortify our presence in oncology, which is a key therapeutic focus area for the company.”

Sujesh Vasudevan
President – India Formulations, Middle East and Africa,
Glenmark

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Copyright © 2024 Medical Buyer

error: Content is protected !!